ATXI Plunges On Thumbs-down, VYGR’s Huntington’s Disease Trial On Hold, Deal Or No Deal For SURF?

Today’s Daily Dose brings you news about FDA declining approval for Avenue Therapeutics/Fortress Biotech’s pain drug IV Tramadol, encouraging data from Gilead/ Galapagos’ Ulcerative Colitis trial, reports of Surface Oncology receiving a takeover offer from GlaxoSmithKline, and clinical hold slapped by the FDA on Voyager’s Huntington’s disease trial.
RTT – Top Story

SPECIAL NEWS UPDATE:

Click today to request your free ACRX discount prescription card and save up to 80% off of your medicine!

SPECIAL DONATION REQUEST UPDATE:

Please help American Consultants Rx achieve it’s biggest goal yet of donating over 30 million discount prescription cards to over 50k organizations in an effort to assist millions of Americans in need. Please click here to donate today!